GlassScriptPhysician profile
Pauline Ho
NPI 1194854794
$6,487.82
in general payments reported to CMS, 2019-2025
23 companies · $2,082 in 2025
The $2,082 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $116 · 2021: $67.10 · 2022: $174 · 2023: $1,267 · 2024: $2,044 · 2025: $2,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,117 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,116.93 |
| Education | $276.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,623.95 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,299.16 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $926.82 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $401.87 | 2023-2025 | |
| Insmed, INC. | $399.49 | 2019-2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $306.21 | 2019-2024 | Cresemba |
| Melinta Therapeutics, LLC | $275.79 | 2023-2025 | Kimyrsa, Rezzayo, Orbactiv |
| Shionogi INC | $225.98 | 2021-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $201.16 | 2023-2025 | Nuzyra |
| Philips North America LLC | $176.07 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Janssen Biotech, INC. | $170.73 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $161.45 | 2019-2024 | Trogarzo, Egrifta |
| Pfizer INC. | $52.98 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $39.22 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.23 | 2023 | Hyqvia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $30.95 | 2023-2025 | Vibativ |
| Allergan, INC. | $29.83 | 2020 | |
| Boston Scientific Corporation | $27.68 | 2024 | Wavewriter Alpha Prime 16 |
| Sumitomo Pharma America, INC. | $27.24 | 2025 | Gemtesa |
| Aimmune Therapeutics, INC. | $22.77 | 2025 | Vowst |
| Mayne Pharma Commercial LLC | $22.58 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.32 | 2019 | |
| Napo Pharmaceuticals INC | $14.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pauline Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.